Avacta Group plc (AIM: AVCT), a life sciences company that specialises in targeted cancer treatments and diagnostics, announced on Monday that it will present updated clinical data on its lead candidate, AVA6000, at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from 13-17 September 2024.

The presentation will showcase findings from the Phase 1a trial of AVA6000, a peptide drug conjugate designed to deliver doxorubicin selectively to Fibroblast Activation Protein (FAP)-positive solid tumours. The drug conjugate utilizes Avacta's proprietary pre|CISION™ platform, which leverages FAP's presence in the tumour microenvironment to activate the drug locally, reducing toxicity and improving safety over conventional doxorubicin treatments.

This new data is expected to further validate the efficacy and safety improvements of AVA6000, advancing its development as a promising therapeutic for cancer treatment. Avacta continues to progress its oncology pipeline, aiming to reduce the systemic side effects of cancer drugs through its targeted delivery platforms, pre|CISION and Affimer.

The updated trial results follow early indications of improved safety and preliminary signs of clinical activity in patients with FAP-positive tumours.